Figure 3
Novel aberrations by microarray. (A) Microarray results for case 11 showing a 3.6-Mb gain (shaded in pink) encompassing 5q35.2q35.3 that includes CDHR2, a tumor suppressor candidate. Probes are ordered on the x-axis according to physical mapping positions, with the most proximal 5q probes on the left and the most distal 5q probes on the right. (B) Microarray results for case 17 showing a 4.8-Mb deletion (shaded in blue) at 10q23.31q23.33 that includes MIR107 and FAS. Probes are ordered on the x-axis according to physical mapping positions, with the most proximal 10q probes on the left and the most distal 10q probes on the right. (C) Microarray results for cases 25 and 32 with deletions (shaded in blue) of 3p21.31 that include CDC25A. Case 25 has a 2.2-Mb deletion, and case 32 has a 3.1-Mb deletion. CDC25A is required for progression from G1 to S phase in the cell cycle. Probes are ordered on the x-axis according to physical mapping positions, with the most distal 3p probes on the left and the most proximal 3p probes on the right. For A–C, values along the y-axis represent log2 ratios of patient:control signal intensities. Results are visualized using Oncoglyphix (Signature Genomics).